The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for the Liver Cirrhosis Network
ID: RFA-DK-20-003_RFA-DK-20-004Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NICHDBETHESDA, MD, 20817, USA

PSC

MEDICAL- OTHER (Q999)

Original Source

https://sam.gov/opp/6c0f221213ef48c998012cfaeffcfe1d/view
Timeline
    Description

    Special Notice HEALTH AND HUMAN SERVICES, DEPARTMENT OF seeks industry partners for clinical research collaborations on therapeutics, diagnostics or devices for the Liver Cirrhosis Network. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is looking for industry collaborators to provide novel or repurposed therapeutic agents, diagnostic markers, biomarkers, devices, or services for use in NIH-sponsored multi-center clinical trials and ancillary studies in adult patients with advanced liver disease and cirrhosis. The Liver Cirrhosis Network aims to promote clinical and translational research on cirrhosis of the liver and related complications in adults. The network is interested in conducting research that will lead to improved clinical outcomes in adults with cirrhosis and advanced liver disease. Commercial organizations interested in pursuing clinical collaborations with NIDDK for cirrhosis liver disease are required to submit a Capability Statement to the NIDDK.

    Point(s) of Contact
    Agnes Rooke, JD
    (301) 451-6072
    Agnes.Rooke@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases
    Buyer not available
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking industry partners for clinical research collaborations focused on therapeutics, diagnostics, or devices for childhood cholestatic liver diseases. The initiative aims to engage collaborators in providing novel therapeutic agents and diagnostic tools for use in NIH-sponsored multi-center clinical trials targeting conditions such as biliary atresia and alpha-one antitrypsin deficiency, among others. This collaboration is critical for advancing research and improving clinical outcomes for children suffering from these rare liver diseases. Interested organizations must submit a Capability Statement detailing their proposed solutions and capabilities, with no funding provided by NIDDK for this opportunity. For inquiries, contact Edward Doo at dooe@niddk.nih.gov or Katrina Loh at katrina.loh@nih.gov.
    Industry Collaboration for the Kidney Precision Medicine Project (KPMP)
    Buyer not available
    Special Notice: HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking Industry collaborators for the Kidney Precision Medicine Project (KPMP). This project aims to conduct multi-center clinical and molecular studies in individuals with Diabetic Kidney Disease, Hypertension-related Chronic Kidney Disease, or Acute Kidney Injury. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) is leading this initiative. Industry collaboration is sought to support the research and development efforts in these areas of kidney diseases.
    Vendor Collaboration - MULTI-CENTER CLINICAL TRIALS OF NOVEL THERAPIES FOR PATIENTS WITH WELL CHARACTERIZED GASTROPARESIS
    Buyer not available
    Special Notice: Vendor Collaboration - MULTI-CENTER CLINICAL TRIALS OF NOVEL THERAPIES FOR PATIENTS WITH WELL CHARACTERIZED GASTROPARESIS This federal procurement notice is seeking vendors to collaborate on multi-center clinical trials of novel therapies for patients with well-characterized gastroparesis. Gastroparesis is a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal pain. The purpose of this procurement is to find vendors who can contribute to the development and testing of new therapies for gastroparesis patients. The trials will involve multiple centers, allowing for a diverse patient population and a comprehensive evaluation of the effectiveness of the therapies. Vendors interested in this opportunity should refer to the uploaded document for collaboration details. For further information, please contact the primary contracting officer, Richard Bailey, at BaileyRichard@mail.nih.gov or 301-402-1139, or the secondary contracting officer, Marlene T. Mireles, at mirelesm@mail.nih.gov or 301-443-7795. By successfully fulfilling this procurement, you will not only contribute to the advancement of medical research but also make a positive impact on the lives of patients suffering from gastroparesis.
    Acquisition of Support Services of an MRI Physicist
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract for the acquisition of support services from an MRI physicist, with a focus on early detection of non-alcoholic steatohepatitis (NASH) and metabolic-associated steatohepatitis (MASH). The contractor will be responsible for identifying non-invasive MRI biomarkers for hepatic inflammation and developing imaging techniques, requiring a PhD and over 15 years of relevant experience in MRI data acquisition and pulse sequence programming. This initiative is critical for addressing diagnostic gaps in differentiating NASH/MASH from benign liver conditions, ultimately aiming to enhance patient outcomes through advanced MRI methodologies. Interested parties may contact Amber Harris at amber.harris@nih.gov, with the contract valued at up to $250,000 and scheduled to span from March 30, 2025, to March 29, 2026.
    L--MedStar Health Interventional Cardiology Services
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking sources for MedStar Health Interventional Cardiology Services. This procurement aims to identify qualified vendors capable of providing specialized interventional cardiology services, which are critical for advancing cardiovascular health and treatment options. The services will support the NIH's mission to improve health outcomes through innovative medical practices and research. Interested parties can reach out to Helmut A. Winffel at helmut.winffel@nih.gov or call +1 301 435 0330 for further information regarding this opportunity.
    Automated Cell Dissociation Apparatus
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure an Automated Cell Dissociation Apparatus to enhance research capabilities in neurodegenerative diseases. The apparatus, specifically the S2 Genomics Singulator 100 Cell Dissociation Platform, is required to facilitate the isolation of single nuclei from human and mouse brain tissues, supporting various cell types while ensuring fast and reproducible tissue dissociation. This procurement is critical for advancing scientific research in areas such as ALS, Parkinson's, and Alzheimer's diseases. Interested vendors should contact Rashiid Cummins at rashiid.cummins@nih.gov, with delivery expected within 60 days post-award.
    Anti-human IgG Fc Capture Biosensors
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified vendors to supply Anti-human IgG Fc Capture Biosensors for research at the Vaccine Research Center (VRC). This Sources Sought Notice, identified as SS-NIAID-25-2255392, aims to assess the capabilities of potential suppliers for biosensors that are compatible with the Octet HTX system, which are crucial for measuring protein interactions in vaccine development efforts against pathogens such as HIV-1 and SARS-CoV-2. Vendors are invited to submit a capability statement by March 12, 2025, detailing their qualifications, while adhering to Small Business Administration size standards and indicating interest in socio-economic business categories. Interested parties should direct their responses through the NIAID's electronic Simplified Acquisition Submission System (eSASS), noting that this notice does not obligate the government to award contracts and that all submissions will be reviewed at the government's discretion. For further inquiries, vendors may contact Leah Hinson at leah.hinson@nih.gov.
    Final Innovative Solutions Opening (ISO) ARPA-H Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID)
    Buyer not available
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the "Final Innovative Solutions Opening (ISO) ARPA-H Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID)" initiative. This program aims to enhance rare disease diagnostics by leveraging advanced data aggregation and analytic techniques, focusing on underdiagnosed populations and the creation of comprehensive datasets to improve diagnostic support tools. The RAPID initiative is structured into two phases over a proposed 4.5-year period, emphasizing equitable access to diagnostics and collaboration with patient networks to validate diagnostic models. Interested applicants can reach out to the RAPID Email Box at RAPID@ARPA-H.gov for further information, with the solicitation providing a critical funding opportunity for innovators in the field.
    Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and biodosimetry devices. The primary objectives are to create effective MCMs that mitigate normal tissue injuries from ionizing radiation and to advance biodosimetry tools that enhance triage and treatment strategies during radiation emergencies. This initiative is crucial for national preparedness against potential radiological incidents, as it aims to address the urgent need for medical interventions and diagnostic capabilities in mass casualty scenarios. Proposals are due by March 19, 2025, with an estimated funding of $2 million annually for successful applicants over a typical three-year contract period, totaling a possible award of $6 million. For further inquiries, interested parties may contact Albert Nguyen at nguyenal@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov.
    Opera Phenix Plus High-Content Screening System (or equal)
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the acquisition of an Opera Phenix Plus High-Content Screening System or an equivalent model to support the Induced Pluripotent Stem Cell Neurodegenerative Diseases Initiative (iNDI) within the Center for Alzheimer’s Disease and Related Dementias (CARD). This advanced imaging system is essential for facilitating research aimed at understanding and developing treatments for Alzheimer's and related neurodegenerative diseases by analyzing cellular responses to genetic variations. The procurement emphasizes the need for features such as automated multi-well plate screening, high-speed image capture, integrated robotic handling, and advanced software capabilities, including machine learning for cell separation and 3D analysis. Interested vendors should contact Iris Merscher at iris.merscher@nih.gov or 301-827-2547, or Karen Mahon at karen.mahon@nih.gov or 301-435-7479 for further details, with a delivery timeline of 12 months post-order.